Public Sector Net Cash Requirement

Revolution Medicines Completes Acquisition of EQRx

Retrieved on: 
Thursday, November 9, 2023

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.

Key Points: 
  • Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs
    REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.
  • Through the acquisition, Revolution Medicines expects to add approximately $1.1 billion in net cash proceeds to its balance sheet, after estimated post-closing EQRx wind-down and transition costs.
  • Each share of common stock of EQRx issued has been converted into the right to receive 0.1112 shares of common stock of Revolution Medicines.
  • EQRx common stock has ceased trading on the Nasdaq Global Market and all EQRx programs are being wound down.

TKO Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 7, 2023

Adjusted EBITDA margin was 43% for the period from September 12, 2023 through September 30, 2023.

Key Points: 
  • Adjusted EBITDA margin was 43% for the period from September 12, 2023 through September 30, 2023.
  • The dividend, which totaled approximately $321 million, was paid on September 29, 2023 to Class A common stockholders of record as of September 22, 2023.
  • As a result of the timing of the consummation of the business combination on September 12, 2023, TKO’s consolidated financial information presented herein include UFC’s results for the three and nine months ended September 30, 2023 and 2022, and only includes WWE’s results for the period from September 12, 2023 through September 30, 2023 following the closing of the transaction.
  • ET on November 7, 2023, to discuss its third quarter 2023 results.

Letter to Stockholders Issued by Diamondback Energy, Inc.

Retrieved on: 
Monday, November 6, 2023

Please see the information regarding forward-looking statements and non-GAAP financial information included at the end of this letter.

Key Points: 
  • Please see the information regarding forward-looking statements and non-GAAP financial information included at the end of this letter.
  • In summary, Diamondback continues to execute on our business plan with our best-in-class cost structure and strong balance sheet.
  • This JV, of which Diamondback retained 30% ownership, creates the largest independent water business in the Midland Basin and brought in proceeds of ~$500 million to Diamondback.
  • Important information regarding forward-looking statements is included in our earnings release furnished to the SEC simultaneously with this letter.

Letter to Stockholders Issued by Diamondback Energy, Inc.

Retrieved on: 
Monday, July 31, 2023

Please see the information regarding forward-looking statements and non-GAAP financial information included at the end of this letter.

Key Points: 
  • Please see the information regarding forward-looking statements and non-GAAP financial information included at the end of this letter.
  • Diamondback continued to execute and exceed expectations in the second quarter, with both oil and total production above the high end of our second quarter guidance ranges.
  • Oil realizations increased quarter over quarter to 97% of West Texas Intermediate ("WTI") pricing for the quarter.
  • Important information regarding forward-looking statements is included in our earnings release furnished to the SEC simultaneously with this letter.

Music Licensing, Inc. (OTC: SONG) Announces Q1 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023

NAPLES, Fla., May 15, 2023 /PRNewswire/ -- Music Licensing, Inc. (OTC: SONG) today announced its financial results for the first quarter ended March 31, 2023.

Key Points: 
  • NAPLES, Fla., May 15, 2023 /PRNewswire/ -- Music Licensing, Inc. (OTC: SONG) today announced its financial results for the first quarter ended March 31, 2023.
  • The company's financial results are reported in USD.
  • Total Revenues for Q1 2023 were $14,978,841, driven by our core services.
  • "We are extremely pleased with our Q1 2023 financial results," said Jake P. Noch, CEO of Music Licensing, Inc. "Our impressive revenues and robust net income demonstrate our commitment to driving growth and creating shareholder value.

Music Licensing, Inc. (OTC:SONG) Announces Q1 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023

Naples, FL, May 15, 2023 (GLOBE NEWSWIRE) -- Music Licensing, Inc. (OTC:SONG) today announced its financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Naples, FL, May 15, 2023 (GLOBE NEWSWIRE) -- Music Licensing, Inc. (OTC:SONG) today announced its financial results for the first quarter ended March 31, 2023.
  • The company's financial results are reported in USD.
  • Total Revenues for Q1 2023 were $14,978,841, driven by our core services.
  • "We are extremely pleased with our Q1 2023 financial results," said Jake P. Noch, CEO of Music Licensing, Inc. "Our impressive revenues and robust net income demonstrate our commitment to driving growth and creating shareholder value.

GLAAM, a Revolutionary Architectural Media Glass Manufacturer, to Become Publicly Traded Through Combination with Jaguar Global Growth Corporation I

Retrieved on: 
Thursday, March 2, 2023

MIAMI and SEOUL, South Korea, March 02, 2023 (GLOBE NEWSWIRE) -- GLAAM, Co., Ltd. (“GLAAM” or the “Company”), a leading designer and manufacturer of architectural display glass, and Jaguar Global Growth Corporation I (Nasdaq: JGGC, JGGCR, and JGGCW) (“Jaguar Global”) have entered into a definitive business combination agreement that would result in GLAAM becoming a publicly traded company. As a result of the business combination, GLAAM and Jaguar Global shareholders will exchange their shares for shares in a new combined company (“NewCo”). Upon closing of the transaction, NewCo is expected to be renamed at a later date, and its ordinary shares are expected to be listed on the Nasdaq Stock Market (“Nasdaq”) under a new ticker symbol.

Key Points: 
  • As a result of the business combination, GLAAM and Jaguar Global shareholders will exchange their shares for shares in a new combined company (“NewCo”).
  • GLAAM is the world’s first and only large-scale provider of architectural media glass.
  • The Company manufactures an integrated architectural IT product, G-Glass, that combines architectural glass with customizable, large-scale digital media display capabilities.
  • ft. installation at the View (Cedars Sinai) Hospital in Qatar, which represented the world’s largest transparent media screen.

SmileDirectClub Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, February 28, 2023

NASHVILLE, Tenn., Feb. 28, 2023 (GLOBE NEWSWIRE) -- SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the first medtech platform for teeth straightening, today announced its financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • NASHVILLE, Tenn., Feb. 28, 2023 (GLOBE NEWSWIRE) -- SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the first medtech platform for teeth straightening, today announced its financial results for the fourth quarter and year ended December 31, 2022.
  • Diluted EPS of $(0.18), consistent with the third quarter of 2022, and an improvement of $0.07 over the prior year period.
  • Fourth quarter unique aligner shipments of 41,462, a 20.8% sequential decrease over 52,367 shipments in the third quarter of 2022.
  • Fourth quarter average aligner gross sales price (“ASP”) of $1,960, a 3% improvement compared to $1,902 for the third quarter of 2022.

Quad Reports Fourth Quarter and Full-Year 2022 Results

Retrieved on: 
Tuesday, February 21, 2023

Quad/Graphics, Inc. (NYSE: QUAD) (“Quad” or the “Company”), today reported results for the fourth quarter and full-year ended December 31, 2022.

Key Points: 
  • Quad/Graphics, Inc. (NYSE: QUAD) (“Quad” or the “Company”), today reported results for the fourth quarter and full-year ended December 31, 2022.
  • Joel Quadracci, Chairman, President & CEO of Quad, said: “We delivered strong 2022 results, outperforming our top-line guidance with an 11% increase in Net Sales when excluding divestitures.
  • We will remain nimble and adjust as necessary to changing economic conditions, while looking ahead for growth opportunities as an MX company.”
    Results for the fourth quarter ended December 31, 2022, include:
    Net Sales — Net Sales were $885 million in the fourth quarter of 2022, an increase of 4% compared to the same period in 2021.
  • Net Loss — Net Loss was $9 million in the fourth quarter of 2022, an improvement of $12 million compared to the fourth quarter of 2021, which had a Net Loss of $21 million.

Catheter Precision’s VIVO™ System Used in More Than 800 Procedures in Leading U.S. and European Hospitals

Retrieved on: 
Thursday, December 1, 2022

Catheter Precisions lead product, VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time.

Key Points: 
  • Catheter Precisions lead product, VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time.
  • Additionally, Catheter Precision is working toward a commercial launch of a vessel closure device, currently planned for the first half of 2023.
  • Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias.
  • It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.